Targeting Functional Cures for Immunological Disorders

Shao-Lee Lin, M.D., Ph.D.

President, Chief Executive Officer and Board Director

Shao-Lee Lin, M.D., Ph.D., is a physician-scientist and biotechnology leader dedicated to discovering and developing transformative medicines for patients living with serious immune-mediated diseases. Throughout her career, she has combined scientific innovation with an unwavering patient-first philosophy, building high-performing teams focused on turning breakthrough science into life-changing therapies.

As President, Chief Executive Officer and Board Director of Cue Biopharma (NASDAQ: CUE), Dr. Lin is leading the company’s mission to develop precision immuno-engineered therapies designed to deliver functional cures for immune disorders with high unmet need. She believes the greatest advances in medicine come from combining bold scientific thinking, urgency, collaboration, and an uncompromising focus on patients.

Over more than 25 years, Dr. Lin has helped bring innovative medicines from discovery through global development and regulatory approval to patients. Before joining Cue Biopharma, she founded ACELYRIN (NASDAQ: SLRN), taking the company from inception to successful public offering within three years while raising more than $1 billion from leading biotechnology investors. She also serves as CEO and Board Chair of AZEO BIO, Inc., a privately held biotechnology company she founded in 2024.

Previously, as the first Chief Scientific Officer and Head of Research & Development at Horizon Therapeutics, Dr. Lin helped transform the company into a leading biopharmaceutical organization. Under her scientific leadership, Horizon secured FDA approval of Tepezza®, the first treatment for the vision-threatening autoimmune condition, thyroid eye disease.

Earlier in her career, Dr. Lin led Therapeutic Areas, Development Excellence, and International Development at AbbVie, where she helped to build and advance a portfolio of important new medicines, including Skyrizi® and Rinvoq®. Her organizations successfully brought multiple blockbuster new therapies from proof of concept to regulatory submissions across global regions and with consistently accelerated timelines. Prior to AbbVie, she served as Vice President of Inflammation and Respiratory Development at Gilead Sciences and held leadership positions of increasing responsibility at Amgen.

Dr. Lin earned her undergraduate degrees in Chemical Engineering and Biochemistry, graduating magna cum laude from Rice University, and received both her M.D. and Ph.D. from the Johns Hopkins University School of Medicine. She was faculty as Clinical Scholar at The Rockefeller University prior to joining industry and has also served as adjunct faculty in medicine at Cornell, UCLA, Stanford, and Northwestern.

In addition to her executive leadership, Dr. Lin has served on the boards of Principia Biopharma (NASDAQ: PRNB; acquired by Sanofi), Third Harmonic Bio (NASDAQ: THRD) and Surrozen (NASDAQ: SRZN), as well as nonprofit organizations including Lake Forest College and the Rice University School of Engineering.

Agnes Lee

Chief Investor Relations & Communications Officer

Agnes Lee is the Chief Investor Relations and Communications Officer at Cue Biopharma. She brings more than 25 years of extensive experience leading investor relations, corporate communications, and financial strategy across publicly traded life sciences and medical device companies during periods of growth and transformation.

Most recently, she served as Chief Investor Relations and Communications Officer and Finance at AZEO BIO, Inc., a privately held company. Prior to that role, she was Senior Vice President of Investor Relations and Communications at ACELYRIN (NASDAQ: SLRN), and previously as Senior Vice President of Investor Relations and Strategy at Inogen (NASDAQ: INGN). She has also held senior investor relations and communications roles at Butterfly Network, Inc. (NASDAQ: BFLY), Fluidigm Corporation (NASDAQ: FLDM), and ResMed Inc., a NYSE and ASX dual-listed company (NYSE, ASX: RMD) and started her investor relations career at Life Technologies (NASDAQ: LIFE) which was acquired by Thermo-Fisher Scientific.

Earlier in her career, she held finance leadership roles at publicly held and related companies: Life Technologies, Applied Biosystems, and Celera Diagnostics where she supported earlier stage and commercialized businesses, and investment banking roles at Salomon Smith Barney and Bank of America Securities. She holds an MBA from the Kellogg School of Management at Northwestern University and a BA from Indiana University Bloomington.

Ron Oyston

Chief Administrative Officer

Ron Oyston is the Chief Administrative Officer at Cue Biopharma, responsible for corporate administration, people strategy, and operational scalability, aligning talent and infrastructure with long-term enterprise value creation.

Ron is a global Chief Administrative Officer and Chief Human Resources Officer with more than 25 years of executive leadership experience across publicly traded and private biotechnology, pharmaceutical, and multinational organizations. He has a strong track record of delivering best-in-class employee experience and keeping patients at the center, while also driving successful growth and innovation across both small, complex, and global organizations. A dual UK and US national, he has lived and worked across the United States, United Kingdom, Europe, the Middle East, India, China, and Dubai, collaborating with global workforces ranging from early-stage biotech teams to organizations of over 6,000 employees.

He previously served as Chief Administrative Officer & Chief Human Resources Officer at AZEO BIO, Inc., a privately held company. Before that, he was Chief Human Resources Officer at ACELYRIN, where he built the HR function from inception, partnered closely with the CEO and Board Compensation Committee, and led people strategy through IPO execution. Prior to that, he held senior executive roles at Horizon Therapeutics, Kerry Group, AbbVie, Abbott Laboratories, Emirates Group, and RBS, leading global organizational scale, M&A integration, entity separation, and enterprise transformation initiatives. He holds a Master of Business Administration Degree from the University of Edinburgh.

Sumita Ray, J.D.

Chief Legal & Compliance Officer & Corporate Secretary

Sumita Ray, J.D. is the Chief Legal & Compliance Officer and Corporate Secretary at Cue Biopharma. She has been in the biotech industry for over 25 years and has held positions as Chief Legal & Compliance Officer for over a decade at various publicly traded companies. She has operated at various companies as an executive leader supporting companies throughout their lifecycles, from inception and pre-clinical studies to commercialization and M&A. Ms. Ray has experience across a wide range of therapeutic areas including immunology and has collaborated with teams to launch and support blockbuster therapies including CRESTOR®, TYSABRI®, IMBRUVICA®, and AVASTIN®.

Prior to joining Cue, she served as Chief Legal Officer and Corporate Secretary at AZEO BIO, Inc., a privately held company. Before that, she was Chief Legal, Compliance & Administrative Officer and Corporate Secretary at Vaxxinity (Nasdaq: VAXX), a formerly public biotechnology company. Prior to that, Ms. Ray held the position of Chief Legal, Compliance & Administrative Officer and Corporate Secretary at the public biotechnology companies of Instil Bio, Inc. (Nasdaq: TIL) and Calithera BioSciences, Inc. (Nasdaq: CALA). Earlier in her career, Ms. Ray held senior and executive leadership roles of increasing responsibility at Astrazeneca, Genentech, Elan Pharmaceuticals and Pharmacyclics. 

Ms. Ray began her career in private practice as a pharmaceutical and products liability litigator at the law firm of Montgomery, McCracken, Walker & Rhoads LLP. She currently serves on the Board of Directors of Biomea Fusion, Inc. (Nasdaq: BMEA), to which she was appointed in July 2021. Ms. Ray holds a Juris Doctor from Temple University School of Law and a B.S. in Microbiology with a minor in Chemistry from the University of Arizona. She is admitted to practice law in Pennsylvania and New Jersey.